MMS Academy Launches Mobile App for Accessing Pharmaceutical Industry Virtual Learning Courses from Anywhere
CANTON, Mich. (October 28, 2020) – MMS Holdings (MMS) – an award-winning, data-focused CRO – announced today that its learning arm, MMS Academy, now offers access to all of its virtual pharmaceutical industry courses through a mobile smart device application. As an innovative convenience, students and working professionals can access course material anytime, anywhere across the globe.
This new mobile app brings many benefits, including:
- View course lectures
- Read course materials
- Send and receive messages
- Check grades
- Receive notifications
“The demand for online learning has grown in continuing and higher education, and a massive uptick in virtual learning this year can be attributed to the COVID-19 pandemic,” says Diederik Van Niekerk, Senior Manager of South African Operations, MMS Holdings. “This digital innovation was a simple way to help further the educational goals of working professionals, as well as students looking for a stable, growing career in the pharmaceutical industry.”
According to a 2019 report from Wiley, approximately 56 percent of online college students used a smartphone or tablet to complete at least some of their online course-related activities. Released to a test group last month, users found the mobile app to be convenient, allowing easy access to courses and more efficient communication when staying in touch.
One MMS Academy student noted, “I truly enjoyed using the mobile app on my tablet to listen to the recordings. It worked perfectly, fitting into my lifestyle, and I was able to listen when convenient for me.”
The app is powered by Canvas, an online learning platform used by k-12, higher education, and corporate learning users, alike. Canvas allows for students, working professionals, faculty, and staff to communicate in an easily accessible virtual setting to create a more conducive environment for learning.
Sign-up for courses in the areas of medical writing, clinical trial transparency, clinical programming, and medical coding now by visiting MMS Academy.
About MMS Holdings
MMS is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for the last three consecutive years. For more information, visit www.mmsholdings.com or follow MMS on LinkedIn.
Suggested For You
news
December 8th, 2021
MMS Holdings Wins 2021 Scrip Award for Best Contract Research Organization
news
October 28th, 2021
Praxis bioresearch seeks support from MMS for Alzheimers Disease Therapeutics
news
September 22nd, 2021
MMS SmartStart™ Tech-Enabled Solution Eases Document Content Creation Process
news
August 18th, 2020
MMS Academy Partners with MPGI in India
news
October 10th, 2019
MMS Holdings Announces Status As A Finalist For Best Contract Research Organization
news
June 27th, 2019
MMS Holdings Launches New Time-Saving Application to Automatically Perform Quality Control and Style Checks for Medical Writers
news
March 13th, 2019
GHP Recognises MMS Holdings in the 2019 Biotechnology Awards Winners
news
August 23rd, 2018
MMS Wins Best Global Biotech CRO in the International Life Sciences Awards 2018
news
May 1st, 2018
MMS Partners with University of Findlay to Provide Medical Writing and Clinical Trial Disclosure Courses
news
November 15th, 2017
MMS Selected by Paratek to Support its NDA Submissions for Omadacycline
news
June 11th, 2014
MMS partners with Wayne State University to place Graduate Students in Scientific Summer Internship Program
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance